$34.24
▼ -2.0% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Overview
52-week range
$13
$38
85% of range
Avg surprise (last 4)
-0.3%
Avg reaction (last 2)
+10.6%
100% positive
Latest IV / EM
63%
EM ±9.8% · $35 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.26 | — | — | — | — | financials |
| Wed May 20, 2026 | Mar/2026 | $-0.46 | $-0.38 | -21.1% | -48.4% | +14.9% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.38 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.17 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.30 | $-0.31 | +3.2% | — | — | earnings |
| Thu May 29, 2025 | Mar/2025 | $-0.31 | $-0.23 | -34.8% | — | +6.4% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $0.23 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.31 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.12 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $6.03 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.40 | — | — | — | — | financials |
| Wed Jun 28, 2023 | Mar/2023 | $-0.20 | $-0.41 | +51.2% | — | — | earnings |
| Sat Dec 31, 2022 | Dec 2022 | $-0.49 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | — | $2M | $2M | $2M | — | $9M | $4M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-366M | — | $-339M | $-306M | $-285M | — | $-274M | $-342M |
| Net income | $-190M | — | $-266M | $-166M | $-223M | — | $169M | $-280M |
| EPS (diluted) | $-0.26 | — | $-0.38 | $-0.17 | $-0.33 | — | $0.23 | $-0.31 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.25B | $1.42B | $1.48B | $1.24B | $1.24B | $2.72B | $1.99B | $1.96B |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $4.74B | $5.17B | $4.66B | $4.51B | $4.62B | $5.00B | $5.36B | $5.80B |
| Total assets | $5.31B | $5.71B | $5.23B | $5.06B | $5.03B | $5.44B | $5.79B | $6.21B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $385M | $416M | $251M | $257M | $217M | $250M | $256M | $626M |
| Total equity | $4.23B | $4.53B | $4.27B | $4.81B | $4.82B | $4.69B | $5.54B | $5.58B |